LT3373959T - Arenavirusų dalelės, kaip vėžio vakcinos - Google Patents

Arenavirusų dalelės, kaip vėžio vakcinos

Info

Publication number: LT3373959T
Authority: LT; Lithuania
Prior art keywords: cancer vaccines; arenavirus particles; arenavirus; particles; vaccines
Prior art date: 2015-11-12

Application number

LTEPPCT/EP2016/076668T

Other languages

English (en)

Inventor

Sarah Schmidt

Klaus Orlinger

Katherine Cohen

Original Assignee

Hookipa Biotech Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-11-12

Filing date

2016-11-04

Publication date

2022-07-25

2016-11-04 Application filed by Hookipa Biotech Gmbh filed Critical Hookipa Biotech Gmbh

2022-07-25 Publication of LT3373959T publication Critical patent/LT3373959T/lt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001104—Epidermal growth factor receptors [EGFR]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001108—Platelet-derived growth factor receptors [PDGFR]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001109—Vascular endothelial growth factor receptors [VEGFR]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/00111—Hepatocyte growth factor receptor [HGFR or c-met]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001111—Immunoglobulin superfamily
- A61K39/001112—CD19 or B4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001111—Immunoglobulin superfamily
- A61K39/001113—CD22, BL-CAM, siglec-2 or sialic acid- binding Ig-related lectin 2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001116—Receptors for cytokines
- A61K39/001117—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR] or CD30
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001122—Ephrin Receptors [Eph]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001124—CD20
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001126—CD38 not IgG
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00113—Growth factors
- A61K39/001135—Vascular endothelial growth factor [VEGF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001136—Cytokines
- A61K39/001138—Tumor necrosis factors [TNF] or CD70
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001136—Cytokines
- A61K39/001139—Colony stimulating factors [CSF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001148—Regulators of development
- A61K39/001149—Cell cycle regulated proteins, e.g. cyclin, CDC, CDK or INK-CCR
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001148—Regulators of development
- A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
- A61K39/001151—Apoptosis related proteins, e.g. survivin or livin p53
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001152—Transcription factors, e.g. SOX or c-MYC
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001152—Transcription factors, e.g. SOX or c-MYC
- A61K39/001153—Wilms tumor 1 [WT1]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001156—Tyrosinase and tyrosinase related proteinases [TRP-1 or TRP-2]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001157—Telomerase or TERT [telomerase reverse transcriptase]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001158—Proteinases
- A61K39/001159—Matrix metalloproteinases [MMP]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001158—Proteinases
- A61K39/00116—Serine proteases, e.g. kallikrein
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001162—Kinases, e.g. Raf or Src
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001164—GTPases, e.g. Ras or Rho
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001166—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001166—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
- A61K39/001168—Mesothelin [MSLN]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
- A61K39/00117—Mucins, e.g. MUC-1
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
- A61K39/001171—Gangliosides, e.g. GM2, GD2 or GD3
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
- A61K39/001172—Sialyl-Thomson-nouvelle antigen [sTn]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001174—Proteoglycans, e.g. glypican, brevican or CSPG4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001176—Heat shock proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00118—Cancer antigens from embryonic or fetal origin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00118—Cancer antigens from embryonic or fetal origin
- A61K39/001182—Carcinoembryonic antigen [CEA]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001186—MAGE
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001188—NY-ESO
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001189—PRAME
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00119—Melanoma antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00119—Melanoma antigens
- A61K39/001191—Melan-A/MART
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00119—Melanoma antigens
- A61K39/001192—Glycoprotein 100 [Gp100]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
- A61K39/001194—Prostate specific antigen [PSA]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
- A61K39/001195—Prostate specific membrane antigen [PSMA]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001196—Fusion proteins originating from gene translocation in cancer cells
- A61K39/001197—Breakpoint cluster region-abelson tyrosine kinase [BCR-ABL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Microbiology (AREA)
Immunology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Oncology (AREA)
Cell Biology (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Developmental Biology & Embryology (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Biomedical Technology (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Vascular Medicine (AREA)
Gynecology & Obstetrics (AREA)
Reproductive Health (AREA)
Pregnancy & Childbirth (AREA)
Biochemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Plant Pathology (AREA)
Biophysics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Physics & Mathematics (AREA)
General Chemical & Material Sciences (AREA)
Inorganic Chemistry (AREA)
Dermatology (AREA)
Gastroenterology & Hepatology (AREA)

LTEPPCT/EP2016/076668T 2015-11-12 2016-11-04 Arenavirusų dalelės, kaip vėžio vakcinos LT3373959T (lt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201562254651P	2015-11-12	2015-11-12
US201562254654P	2015-11-12	2015-11-12
PCT/EP2016/076668 WO2017080920A1 (en)	2015-11-12	2016-11-04	Arenavirus particles as cancer vaccines

Publications (1)

Publication Number	Publication Date
LT3373959T true LT3373959T (lt)	2022-07-25

Family

ID=57345877

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LTEPPCT/EP2016/076668T LT3373959T (lt)	2015-11-12	2016-11-04	Arenavirusų dalelės, kaip vėžio vakcinos

Country Status (16)

Country	Link
US (2)	US11266727B2 (lt)
EP (2)	EP3960197A1 (lt)
JP (2)	JP7157662B2 (lt)
CN (1)	CN108697775B (lt)
AU (1)	AU2016352572B2 (lt)
CA (1)	CA3003548A1 (lt)
DK (1)	DK3373959T3 (lt)
ES (1)	ES2922981T3 (lt)
HR (1)	HRP20221167T1 (lt)
HU (1)	HUE059589T2 (lt)
LT (1)	LT3373959T (lt)
PL (1)	PL3373959T3 (lt)
PT (1)	PT3373959T (lt)
RS (1)	RS63546B1 (lt)
SI (1)	SI3373959T1 (lt)
WO (1)	WO2017080920A1 (lt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2744910C (en)	2007-12-27	2018-01-30	Universitaet Zuerich	Replication-defective arenavirus vectors
ES2868427T3 (es)	2013-12-03	2021-10-21	Hookipa Biotech Ag	Vacunas contra el CMV
AU2015345080B2 (en)	2014-11-13	2022-01-27	Universite De Geneve	Tri-segmented arenaviruses as vaccine vectors
WO2016198531A2 (en)	2015-06-10	2016-12-15	Hookipa Biotech Ag	Hpv vaccines
WO2018045029A1 (en) *	2016-09-02	2018-03-08	The United States Of America, As Represented By The Secretary Of The Army	Pan south american arenavirus live attenuated vaccine
IL259077B2 (en)	2015-11-04	2024-12-01	Hookipa Biotech Gmbh	Vaccines against hepatitis b virus
WO2017080920A1 (en)	2015-11-12	2017-05-18	Hookipa Biotech Ag	Arenavirus particles as cancer vaccines
TWI808055B (zh)	2016-05-11	2023-07-11	美商滬亞生物國際有限公司	Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh)	2016-05-11	2023-03-01	美商滬亞生物國際有限公司	Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
EP3606549A1 (en) *	2017-04-07	2020-02-12	Hookipa Biotech GmbH	Arenavirus particles to treat solid tumors
CA3083231A1 (en) *	2017-11-29	2019-06-06	Adaptive Phage Therapeutics, Inc.	Methods of vaccination using icosahedral phage
US20220226467A1 (en)	2019-06-18	2022-07-21	Janssen Sciences Ireland Unlimited Company	Arenavirus vectors for hepatitis b virus (hbv) vaccines and uses thereof
WO2021089853A1 (en) *	2019-11-07	2021-05-14	Universität Basel	Arenaviruses as vectors
WO2021110919A1 (en)	2019-12-07	2021-06-10	Isa Pharmaceuticals	Treatment of diseases related to hepatitis b virus
CR20220602A (es)	2020-05-29	2023-05-16	Hookipa Biotech Gmbh	Estrategias de tratamiento del cáncer mediante el uso de vectores de arenavirus
CN117241812A (zh) *	2021-02-26	2023-12-15	阿巴洛斯治疗有限公司	用于治疗目的新病毒颗粒
WO2022200373A2 (en)	2021-03-23	2022-09-29	Hookipa Biotech Gmbh	Arenaviruses used in treatments of prostate cancer
WO2023152116A1 (en) *	2022-02-08	2023-08-17	Hookipa Biotech Gmbh	Combination therapy with arenavirus particles and immune checkpoint modulators or cytokines
WO2024223299A2 (en)	2023-04-26	2024-10-31	Isa Pharmaceuticals B.V.	Methods of treating cancer by administering immunogenic compositions and a pd-1 inhibitor

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5057540A (en)	1987-05-29	1991-10-15	Cambridge Biotech Corporation	Saponin adjuvant
US4912094B1 (en)	1988-06-29	1994-02-15	Ribi Immunochem Research Inc.	Modified lipopolysaccharides and process of preparation
JPH1084967A (ja)	1996-09-19	1998-04-07	Fujirebio Inc	Ｂ型肝炎のｅ抗原
FR2803599B1 (fr)	2000-01-06	2004-11-19	Inst Nat Sante Rech Med	Nouveau virus mute de l'hepatite b, ses constituants nucleiques et proteiques et leurs applications
EP2243493A1 (en) *	2002-07-03	2010-10-27	Ono Pharmaceutical Co., Ltd.	Immunopotentiative composition
MX2007013978A (es)	2005-05-09	2008-02-22	Ono Pharmaceutical Co	Anticuerpos monoclonales humanos a muerte programada 1 (pd-1) y metodos para tratamiento de cancer utilizando anticuerpos anti-pd-1 solos o en combinacion con otros inmunoterapeuticos.
WO2006125983A1 (en)	2005-05-23	2006-11-30	Oxxon Therapeutics Ltd	Compositions for inducing an immune response against hepatitis b
US8063063B2 (en)	2006-03-23	2011-11-22	Novartis Ag	Immunopotentiating compounds
ES2376492T3 (es)	2006-03-23	2012-03-14	Novartis Ag	Compuestos de imidazoquinoxalina como inmunomoduladores.
CN103536915A (zh) *	2006-12-27	2014-01-29	埃默里大学	用于治疗传染病和肿瘤的组合物和方法
CA2744910C (en)	2007-12-27	2018-01-30	Universitaet Zuerich	Replication-defective arenavirus vectors
NZ598000A (en)	2009-08-07	2013-10-25	Transgene Sa	Composition for treating hbv infection
GB201001726D0 (en)	2010-02-03	2010-03-24	Univ St Andrews	Bunyavirus vaccine
WO2012162428A1 (en)	2011-05-23	2012-11-29	The United States Of America, As Represented By The Secretary, Department Of Health & Human Services	Prime-boost vaccination for viral infection
WO2013112549A1 (en)	2012-01-24	2013-08-01	Sanford Research/USD	Polynucleotides for treating oncogenic viral polypeptide positive tumors
ES2751423T3 (es)	2013-03-15	2020-03-31	Univ Geneve	Vacunas antimicobacterianas
GB201305361D0 (en)	2013-03-25	2013-05-08	Univ Edinburgh	Enhanced expression
ES2868427T3 (es)	2013-12-03	2021-10-21	Hookipa Biotech Ag	Vacunas contra el CMV
KR20220062143A (ko) *	2014-01-06	2022-05-13	더 트러스티스 오브 더 유니버시티 오브 펜실바니아	Pd1 및 pdl1 항체 및 백신 조합 및 면역요법을 위한 이들의 사용
WO2015183895A1 (en)	2014-05-27	2015-12-03	University Of Rochester	Novel arenavirus vaccine
US9943585B2 (en)	2014-07-30	2018-04-17	University Of Rochester	Methods and compositions related to reorganization of arenavirus genome for development of novel arenavirus live-attenuated vaccines (LAV)
MX391006B (es)	2014-09-22	2025-03-21	Univ Minnesota	Sistema de genética inversa del virus pichindé y métodos de uso.
GB201419572D0 (en)	2014-11-03	2014-12-17	Pirbright Inst The	Virus
AU2015345080B2 (en) *	2014-11-13	2022-01-27	Universite De Geneve	Tri-segmented arenaviruses as vaccine vectors
ES2929532T3 (es) *	2015-01-29	2022-11-30	Univ Pennsylvania	Combinaciones de inhibidores de puntos de control y vacunas y su uso en inmunoterapia
DE102015207036A1 (de)	2015-04-17	2016-10-20	Karl Sebastian Lang	Arenaviren zur Anwendung bei der Behandlung und/oder Vorbeugung von Tumoren sowie Verfahren zur Herstellung von Arenaviren mit (verbesserten) tumorregressiven Eigenschaften
WO2016198531A2 (en)	2015-06-10	2016-12-15	Hookipa Biotech Ag	Hpv vaccines
EP3365005B1 (en)	2015-10-23	2025-04-09	Institut Pasteur	Recombinant mopeia virus and vaccine platform
IL259077B2 (en)	2015-11-04	2024-12-01	Hookipa Biotech Gmbh	Vaccines against hepatitis b virus
WO2017080920A1 (en)	2015-11-12	2017-05-18	Hookipa Biotech Ag	Arenavirus particles as cancer vaccines
US10980877B2 (en)	2016-04-28	2021-04-20	The University Of Chicago	Method for treating melanoma using lymphangiogenesis inducers and a melanoma-specific antigen
KR102671785B1 (ko)	2016-05-18	2024-06-04	유니버시타트 바셀	백신 벡터로서 3개의 세그먼트를 가진 피친드 바이러스
CA3039356A1 (en)	2016-11-04	2018-05-11	Hookipa Biotech Gmbh	Replication-deficient arenavirus particles and tri-segmented arenavirus particles as cancer vaccines
EP3606549A1 (en)	2017-04-07	2020-02-12	Hookipa Biotech GmbH	Arenavirus particles to treat solid tumors
WO2021089853A1 (en)	2019-11-07	2021-05-14	Universität Basel	Arenaviruses as vectors

2016
- 2016-11-04 WO PCT/EP2016/076668 patent/WO2017080920A1/en not_active Ceased
- 2016-11-04 CN CN201680078633.1A patent/CN108697775B/zh active Active
- 2016-11-04 HR HRP20221167TT patent/HRP20221167T1/hr unknown
- 2016-11-04 PL PL16797775.0T patent/PL3373959T3/pl unknown
- 2016-11-04 PT PT167977750T patent/PT3373959T/pt unknown
- 2016-11-04 US US15/775,360 patent/US11266727B2/en active Active
- 2016-11-04 AU AU2016352572A patent/AU2016352572B2/en active Active
- 2016-11-04 JP JP2018524447A patent/JP7157662B2/ja active Active
- 2016-11-04 RS RS20220825A patent/RS63546B1/sr unknown
- 2016-11-04 CA CA3003548A patent/CA3003548A1/en active Pending
- 2016-11-04 ES ES16797775T patent/ES2922981T3/es active Active
- 2016-11-04 DK DK16797775.0T patent/DK3373959T3/da active
- 2016-11-04 EP EP21182026.1A patent/EP3960197A1/en active Pending
- 2016-11-04 EP EP16797775.0A patent/EP3373959B1/en active Active
- 2016-11-04 SI SI201631604T patent/SI3373959T1/sl unknown
- 2016-11-04 HU HUE16797775A patent/HUE059589T2/hu unknown
- 2016-11-04 LT LTEPPCT/EP2016/076668T patent/LT3373959T/lt unknown
2021
- 2021-11-02 JP JP2021179213A patent/JP2022033736A/ja active Pending
2022
- 2022-01-24 US US17/582,682 patent/US20220257734A1/en active Pending

Also Published As

Publication number	Publication date
EP3373959A1 (en)	2018-09-19
SI3373959T1 (sl)	2022-11-30
CA3003548A1 (en)	2017-05-18
DK3373959T3 (da)	2022-09-19
PL3373959T3 (pl)	2022-10-24
ES2922981T3 (es)	2022-09-22
CN108697775B (zh)	2023-05-09
PT3373959T (pt)	2022-08-09
US20220257734A1 (en)	2022-08-18
JP7157662B2 (ja)	2022-10-20
RS63546B1 (sr)	2022-09-30
US11266727B2 (en)	2022-03-08
WO2017080920A1 (en)	2017-05-18
AU2016352572B2 (en)	2023-10-19
EP3960197A1 (en)	2022-03-02
AU2016352572A1 (en)	2018-05-17
HRP20221167T1 (hr)	2022-12-09
JP2022033736A (ja)	2022-03-02
CN108697775A (zh)	2018-10-23
US20180344830A1 (en)	2018-12-06
EP3373959B1 (en)	2022-06-29
JP2018533604A (ja)	2018-11-15
HUE059589T2 (hu)	2022-12-28

Publication	Publication Date	Title
ZA202005298B (en)	2022-02-23	Combination tumor immunotherapy
SI3373959T1 (sl)	2022-11-30	Arenavirusni delci kot cepiva proti raku
IL251464A0 (en)	2017-05-29	Combination therapy for cancer
GB201410971D0 (en)	2014-08-06	Vaccine
GB201518684D0 (en)	2015-12-02	Vaccine
IL249898A0 (en)	2017-03-30	Combined cancer treatment
IL246761A0 (en)	2016-08-31	Combined cancer treatment
IL255560A (en)	2018-01-31	Macrophinocytosis in cancer
GB201522132D0 (en)	2016-01-27	Vaccine
IL277752A (en)	2020-11-30	Cancer vaccines
EP3122375A4 (en)	2018-04-18	Breast and ovarian cancer vaccines
HUE064499T2 (hu)	2024-03-28	Hiszton rákellenes vakcinák
GB201608821D0 (en)	2016-07-06	Vaccines
GB201519734D0 (en)	2015-12-23	Cancer therapy
GB201508480D0 (en)	2015-07-01	Cancer
SI3188755T1 (sl)	2021-03-31	Cepivo
ZA201708393B (en)	2019-06-26	Large particles
GB201417214D0 (en)	2014-11-12	Vaccine
GB201406628D0 (en)	2014-05-28	Vaccine
HK1259853A1 (en)	2019-12-06	Cancer vaccines
GB201518917D0 (en)	2015-12-09	Vaccination
GB201503266D0 (en)	2015-04-15	Vaccination
GB201411884D0 (en)	2014-08-20	Cancer therapy
GB201521608D0 (en)	2016-01-20	Vaccine composition
GB201507344D0 (en)	2015-06-10	Novel particles